Tzekaki E E, Tsolaki M, Pantazaki A A, Geromichalos G, Lazarou E, Kozori M, Sinakos Z
Laboratory of Biochemistry, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Hell J Nucl Med. 2019 Sep-Dec;22 Suppl 2:181.
Although Mediterranean diet is connected with longevity and lower rate of many disorders including Alzheimer's disease (AD), the effect of olive oil, which is the principal component of the Mediterranean diet, on fibrinolytic system related to AD and especially on plasminogen activator inhibitor-1 (PAI-1) and a2-antiplasmin in aged participants are not yet examined. This study was performed on 108 aged participants allocated into 5 groups: Mild Cognitive Impairment (MCI) (36) patients subjected to 1-year therapy with extra virgin olive oil (EVOO), MCI without therapy patients (26), MCI without therapy 1-year later patients (11), AD patients (30) and healthy individuals (16). Hypothesis/Purpose: To examine the effect of EVOO therapy on the fibrinolytic factors PAI-1 and a2-antiplasmin, on hallmarks of AD, tau and Aβ amyloid fragments and on an oxidative stress biomarker, MDA in the serum of MCI patients aiming to be exploited as a future preventive therapy.
Using ELISA method, the levels of both fibrinolytic factors PAI-1 and a2- antiplasmin in the serum of MCI patients were reduced notably in the EVOO treated patients versus the control group and were lower than those of all other groups. For better determination of AD from other pathological conditions the ratio Aβ1-42/Aβ1-40 was measured in serum of all participants. The more lessened the ratio is, the more cognitive impairment is observed in patients. The MCI group with one-year EVOO therapy displayed a ratio similar to this of healthy individuals. Moreover, patients with EVOO therapy showed decreased tau protein levels in comparison with all the other groups. The levels of the oxidative stress's biomarker, malondialdehyde (MDA) showed a significant decrease in MCI patients subjected to EVOO therapy revealing the involvement of the beneficial antioxidative properties of EVOO in the progression of AD.
We demonstrated that EVOO therapy may prevent the risk of patients with MCI to progress to AD via decreasing fibrinolytic factors PAI-1 and a2 antiplasmin that reflecting in the diminution of the hallmarks proteins of AD, tau and Aβ amyloid as well and in a biomarker of oxidative stress, MDA.
尽管地中海饮食与长寿以及包括阿尔茨海默病(AD)在内的多种疾病的低发病率相关,但地中海饮食的主要成分橄榄油对与AD相关的纤维蛋白溶解系统,特别是对老年参与者的纤溶酶原激活物抑制剂-1(PAI-1)和α2-抗纤溶酶的影响尚未得到研究。本研究对108名老年参与者进行,分为5组:轻度认知障碍(MCI)患者(36名),接受1年特级初榨橄榄油(EVOO)治疗;未接受治疗的MCI患者(26名);1年后未接受治疗的MCI患者(11名);AD患者(30名);健康个体(16名)。假设/目的:研究EVOO治疗对MCI患者血清中纤维蛋白溶解因子PAI-1和α2-抗纤溶酶、AD标志物tau和Aβ淀粉样蛋白片段以及氧化应激生物标志物丙二醛(MDA)的影响,旨在将其作为未来的预防性治疗方法。
使用酶联免疫吸附测定(ELISA)方法,与对照组相比,接受EVOO治疗的MCI患者血清中纤维蛋白溶解因子PAI-1和α2-抗纤溶酶的水平显著降低,且低于所有其他组。为了更好地从其他病理状况中鉴别AD,在所有参与者的血清中测量了Aβ1-42/Aβ1-40比值。该比值降低得越多,患者的认知障碍越明显。接受1年EVOO治疗的MCI组的比值与健康个体相似。此外,与所有其他组相比,接受EVOO治疗的患者tau蛋白水平降低。氧化应激生物标志物丙二醛(MDA)的水平在接受EVOO治疗的MCI患者中显著降低,揭示了EVOO有益的抗氧化特性在AD进展中的作用。
我们证明,EVOO治疗可能通过降低纤维蛋白溶解因子PAI-1和α2抗纤溶酶,预防MCI患者进展为AD风险,这表现为AD标志性蛋白tau和Aβ淀粉样蛋白减少,以及氧化应激生物标志物MDA减少。